Last day of trading in shares with pre-emptive rights in connection with rights issue

Aquaporin A/S announced the last cum-rights trading day for its rights issue and detailed the timetable and terms: shareholders registered on 6 Jan 2026 (5:59 p.m. CET) receive ten pre-emptive rights per existing share; the subscription ratio is 10:3 (three rights required for one new share) at a subscription price of DKK 1. Rights trade from 5–16 Jan 2026 and the subscription period runs 7–20 Jan 2026; unexercised rights will lapse. The company warns of material dilution—up to 77% if all new shares are subscribed—creating notable potential share overhang and liquidity/valuation pressure for existing holders. Contact and regulatory/prospectus disclaimers are provided; new shares are to be admitted to trading on Nasdaq Copenhagen.

Analysis

Market structure: The rights issue (10 rights per share; 10:3 subscription) will increase Aquaporin’s share count ~4.33x if fully subscribed, producing up to 77% dilution and a mechanically lower TERP (theoretical ex-rights price) effective after 17:00 CET Jan 2. Immediate winners are cash-rich investors and rights/arbitrageurs; losers are passive existing holders who don’t inject ~DKK3.333 per share to maintain ownership. Liquidity will bifurcate between shares (selling pressure ex-rights) and a short-lived rights market (Jan 5–16) that creates trading opportunities.

Risk assessment: Tail risks include a failed placement or low subscription rate forcing a deeper rescue (further dilution or debt) — a >20% additional equity raise is possible and would be credit-negative. Time horizons: immediate (days) = ex-rights mechanical price drop; short-term (weeks) = rights trading and subscription outcome; long-term (quarters) = whether proceeds fund commercial roll-out or simply cover burn. Hidden dependencies: lack of disclosed use-of-proceeds and concentration of institutional support; announcement of anchor investors or strategic buyers would flip sentiment quickly.

Trade implications: Direct plays — existing holders must choose: (A) fully subscribe by Jan 20 (cash requirement = DKK3.333/share) to avoid dilution, or (B) sell ahead of ex-rights (close by 17:00 CET Jan 2). Tactical trades — buy rights between Jan 5–16 if per-right quotes imply >20% uplift to immediate market-exercise economics (suggest entry if per-right <DKK0.30 and spot >DKK1.50); alternatively initiate small put spreads (notional 1–2% portfolio) to capture a 20–40% downside into subscription closure. Pair trade — short Aquaporin vs long established water-techs (e.g., XYL, PNR) to isolate company-specific dilution risk.

Contrarian angles: Consensus underestimates upside if proceeds are deployed to commercial scale — if subscription is high and funds are earmarked for revenue-driving projects, post-raise re-rating of 30–70% is plausible over 6–18 months. The market may be over-discounting Aquaporin now; consider a staged re-entry after subscription completion and receipt-use disclosure, buying at >30% discount to TERP with 12–18 month hold. Historical parallels: biotech/cleantech dilutive raises often see sharp near-term drops then recover once capital converts into commercial milestones.

Key Decisions for Investors

• If you are an existing Aquaporin shareholder: either subscribe pro rata by Jan 20 to maintain ownership (cash required = DKK3.333 per existing share) or liquidate your position before 17:00 CET on Jan 2 to avoid automatic ex-rights dilution; allocate no more than 2–3% of portfolio NAV to maintain position unless you have conviction on use-of-proceeds.
• Opportunistic rights strategy (Jan 5–16): buy pre-emptive rights size 1% NAV if per-right market price < DKK0.30 and spot share price > DKK1.50 (exercise at DKK1 yields >20% immediate arbitrage); exercise rights before Jan 20 and sell post-subscription if market re-rates.
• Tactical downside hedge: initiate a put-spread on Aquaporin (buy 3–6 month puts, sell lower-strike puts) sized 1–2% NAV to capture an expected 20–40% post-ex-rights correction; close position within 30 days after subscription outcome or on a 15% adverse move.
• Relative-value pair trade: short Aquaporin (size 1–2% NAV) vs equal-weight long positions in established water-tech names Xylem (XYL) and Pentair (PNR) to neutralize sector beta; rebalance after subscription completion and upon disclosure of capital deployment (target horizon 3–6 months).